Fexofenadine sales will expand through 2036, with powder at 63.4% within the form segment and ≥99.5% at 68.8% of the purity grade category in 2026. The market is estimated at USD 45.4 million in 2026 and is forecast to record a 4.4% CAGR between 2026 and 2036.